These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21997489)

  • 21. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
    Linde M
    Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759
    [No Abstract]   [Full Text] [Related]  

  • 22. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute respiratory manifestations of the abacavir hypersensitivity reaction.
    Herring SJ; Krieger AC
    AIDS; 2006 Jan; 20(2):301-2. PubMed ID: 16511430
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypersensitivity reactions due to abacavir.
    Newsline People AIDS Coalit N Y; 1998 Feb; ():35-6. PubMed ID: 11367446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir and cardiovascular disease: A critical look at the data.
    Llibre JM; Hill A
    Antiviral Res; 2016 Aug; 132():116-21. PubMed ID: 27260856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
    Bellagamba R; Tommasi C; De Marco M; Narciso P
    J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
    [No Abstract]   [Full Text] [Related]  

  • 29. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 30. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
    Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
    AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
    [No Abstract]   [Full Text] [Related]  

  • 31. Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?
    Fichtenbaum CJ; Mallon P
    AIDS; 2023 Mar; 37(3):541-543. PubMed ID: 36695364
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.
    Soler Palacin P; Aramburo A; Moraga FA; Cabañas MJ; Figueras C
    Pediatr Infect Dis J; 2006 Apr; 25(4):382. PubMed ID: 16568000
    [No Abstract]   [Full Text] [Related]  

  • 33. [Observational study with abacavir. Decreased viral load and quality of life improves].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():52-3. PubMed ID: 11373782
    [No Abstract]   [Full Text] [Related]  

  • 34. Fatal lactic acidosis associated with tenofovir and abacavir.
    Giola M; Basilico C; Grossi P
    Int J Infect Dis; 2005 Jul; 9(4):228-9. PubMed ID: 15916912
    [No Abstract]   [Full Text] [Related]  

  • 35. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
    Schafer JJ; Short WR; Squires KE
    Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
    Young J; Xiao Y; Moodie EE; Abrahamowicz M; Klein MB; Bernasconi E; Schmid P; Calmy A; Cavassini M; Cusini A; Weber R; Bucher HC;
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):413-21. PubMed ID: 25932884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe metabolic acidosis and Fanconi syndrome during stavudine and abacavir therapy in a resource-limited setting.
    Bansie RD; Vreden SG
    Braz J Infect Dis; 2012; 16(6):610-1. PubMed ID: 23141987
    [No Abstract]   [Full Text] [Related]  

  • 39. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 40. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.